Prehypertension and risk of cardiovascular disease

References

• vandenHoogen PC, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A, Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N. Engl. J. Med. 342, 1–8 (2000).
   PubMedGoogle Scholar
• Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 275, 1571–1576 (1996).
   PubMed Web of Science ®Google Scholar
• Whelton PK. Epidemiology of hypertension. Lancet 344, 101–106 (1994).
   PubMed Web of Science ®Google Scholar
• Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch. Intern. Med. 153, 598–615 (1993).
   PubMed Web of Science ®Google Scholar
• Lowe LP, Greenland P, Ruth KJ, Dyer AR, Stamler R, Stamler J. Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men. Arch. Intern. Med. 158, 2007–2014 (1998).
   PubMed Web of Science ®Google Scholar
• O’Donnell CJ, Ridker PM, Glynn RJ et al. Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians. Circulation 95, 1132–7 (1997).
   PubMedGoogle Scholar
• MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335, 765–74 (1990).
   Google Scholar
• Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903–1913 (2002).
   PubMed Web of Science ®Google Scholar
• Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J. Hypertens. 21, 1983–1992 (2003).
   PubMed Web of Science ®Google Scholar
• The World Health Report 2002: Risks to Health. WHO, Geneva, Switzerland. (2002).
   Google Scholar
• Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335, 827–38 (1990).
   PubMed Web of Science ®Google Scholar
• Psaty BM, Lumley T, Furberg CD et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 289, 2534–2544 (2003).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• ESH-ESC. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21, 1011–1053 (2003).
   PubMed Web of Science ®Google Scholar
• Hemmelgarn BR, Zarnke KB, Campbell NR et al. The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I-Blood pressure measurement, diagnosis and assessment of risk. Can. J. Cardiol. 20, 31–40 (2004).
   PubMed Web of Science ®Google Scholar
• Saruta T. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Nippon. Rinsho. 63, 952–958 (2005).
   PubMedGoogle Scholar
• Williams B, Poulter NR, Brown MJ et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J. Hum. Hypertens. 18, 139–185 (2004).
   PubMed Web of Science ®Google Scholar
• The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch. Intern. Med. 157, 2413–2446 (1997).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289, 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Vasan RS, Larson MG, Leip EP et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N. Engl. J. Med. 345, 1291–1297 (2001).
   PubMed Web of Science ®Google Scholar
• Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 358, 1682–1686 (2001).
   PubMed Web of Science ®Google Scholar
• Freitag MH, Vasan RS. What is normal blood pressure? Curr. Opin. Nephrol. Hypertens. 12, 285–292 (2003).
   PubMedGoogle Scholar
• Kannel WB, Vasan RS, Levy D. Is the relation of systolic blood pressure to risk of cardiovascular disease continuous and graded, or are there critical values? Hypertension 42, 453–456 (2003).
   PubMed Web of Science ®Google Scholar
• Greenlund KJ, Croft JB, Mensah GA. Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999–2000. Arch. Intern. Med. 164, 2113–2118 (2004).
   PubMedGoogle Scholar
• Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new Joint National Committee guidelines: new challenges of the old problem. Arch. Intern. Med. 164, 2126–2134 (2004).
   PubMed Web of Science ®Google Scholar
• Qureshi AI, Suri FK, Kirmani JF, Divani AA. Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000. Med. Sci. Monit. 11, CR403–CR409 (2005).
   PubMedGoogle Scholar
• Liszka HA, Mainous AG, III, King DE, Everett CJ, Egan BM. Prehypertension and cardiovascular morbidity. Ann. Fam. Med. 3, 294–299 (2005).
   PubMed Web of Science ®Google Scholar
• King DE, Egan BM, Mainous AG, III, Geesey ME. Elevation of C-reactive protein in people with prehypertension. J. Clin. Hypertens. (Greenwich) 6, 562–568 (2004).
   PubMedGoogle Scholar
• Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: The ATTICA Study. Am. J. Hypertens 17, 568–573 (2004).
   Google Scholar
• Toikka JO, Laine H, Ahotupa M et al. Increased arterial intima-media thickness and in vivo LDL oxidation in young men with borderline hypertension. Hypertension 36, 929–933 (2000).
   PubMed Web of Science ®Google Scholar
• Qureshi AI, Suri MF, Kirmani JF, Divani AA, Mohammad Y. Is prehypertension a risk factor for cardiovascular diseases? Stroke 36, 1859–63 (2005).
   PubMed Web of Science ®Google Scholar
• Winegarden CR. From ‘prehypertension’ to hypertension? Additional evidence. Ann. Epidemiol. 15, 720–725 (2005).
   PubMed Web of Science ®Google Scholar
• Mainous AG, III, Everett CJ, Liszka H, King DE, Egan BM. Prehypertension and mortality in a nationally representative cohort. Am. J. Cardiol. 94, 1496–1500 (2004).
   PubMed Web of Science ®Google Scholar
• Bowman TS, Sesso HD, Glynn RJ, Gaziano JM. JNC 7 category and risk of cardiovascular death in men: are there differences by age? Am. J. Geriatr. Cardiol. 14, 126–131 (2005).
   PubMed Web of Science ®Google Scholar
• Russell LB, Valiyeva E, Carson JL. Effects of prehypertension on admissions and deaths: a simulation. Arch. Intern. Med. 164, 2119–2124 (2004).
   PubMed Web of Science ®Google Scholar
• Wang TJ, Vasan RS. Epidemiology of uncontrolled hypertension in the United States. Circulation 112, 1651–1662 (2005).
   PubMed Web of Science ®Google Scholar
• Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 290, 199–206 (2003).
   Google Scholar
• Stevens VJ, Obarzanek E, Cook NR et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, Phase II. Ann. Intern. Med. 134, 1–11 (2001).
   PubMed Web of Science ®Google Scholar
• Hagberg JM, Park JJ, Brown MD. The role of exercise training in the treatment of hypertension: an update. Sports Med. 30, 193–206 (2000).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Svetkey LP, Vollmer WM et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N. Engl. J. Med. 344, 3–10 (2001).
   PubMed Web of Science ®Google Scholar
• Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet 365, 434–441 (2005).
   PubMed Web of Science ®Google Scholar
• Pyorala K, Wood D. Prevention of coronary heart disease in clinical practice. European recommendations revised and reinforced. Eur. Heart J. 19, 1413–1415 (1998).
   PubMed Web of Science ®Google Scholar
• Alderman MH. Blood pressure management: individualized treatment based on absolute risk and the potential for benefit. Ann. Intern. Med. 119, 329–335 (1993).
   PubMed Web of Science ®Google Scholar
• Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285, 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• Bosch J, Yusuf S, Pogue J et al. Use of ramipril in preventing stroke: double-blind randomised trial. BMJ 324, 699–702 (2002).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292, 2217–2225 (2004).
   PubMed Web of Science ®Google Scholar
• Chalmers J, MacMahon S. Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS): interpretation and implementation. J. Hypertens. Suppl. 21, S9–S14 (2003).
   Google Scholar
• Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N. Engl. J. Med. 348, 383–393 (2003).
   PubMed Web of Science ®Google Scholar
• Mein CA, Caulfield MJ, Munroe PB. Selection of candidate genes in hypertension. Methods Mol. Med. 108, 107–130 (2004).
   Google Scholar
• Kurland L, Lind L, Melhus H. Using genotyping to predict responses to antihypertensive treatment. Trends Pharmacol. Sci. 26, 443–447 (2005).
   PubMedGoogle Scholar
• Wang TJ, Evans JC, Meigs JB et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation 111, 1370–1376 (2005).
   PubMed Web of Science ®Google Scholar
• Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 290, 2945–2951 (2003).
   PubMed Web of Science ®Google Scholar
• Pater C. The blood pressure ‘uncertainty range’ – a pragmatic approach to overcome current diagnostic uncertainties (II). Curr. Control Trials Cardiovasc. Med. 6, 5 (2005).
   PubMedGoogle Scholar
• Susic D, Varagic J, Ahn J, Frohlich ED. Collagen cross-link breakers: a beginning of a new era in the treatment of cardiovascular changes associated with aging, diabetes, and hypertension. Curr. Drug Targets Cardiovasc. Haematol. Disord. 4, 97–101 (2004).
   PubMedGoogle Scholar